Alpine Immune Sciences, Inc. (ALPN): Price and Financial Metrics

Alpine Immune Sciences, Inc. (ALPN): $64.97

0.01 (+0.02%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add ALPN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#269 of 360

in industry

ALPN Price/Volume Stats

Current price $64.97 52-week high $65.00
Prev. close $64.96 52-week low $8.33
Day low $64.97 Volume 4,288,300
Day high $65.00 Avg. volume 1,917,072
50-day MA $52.49 Dividend yield N/A
200-day MA $26.27 Market Cap 4.46B

ALPN Stock Price Chart Interactive Chart >


Alpine Immune Sciences, Inc. (ALPN) Company Bio


Alpine Immune Sciences, Inc. is focused on developing novel protein‐based immunotherapies using its proprietary Variant Ig Domain vIgD platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which can potentially produce proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to both oncology and inflammatory diseases. The company formed following a July, 2017 merger with Nivalis Therapeutics.


ALPN Latest News Stream


Event/Time News Detail
Loading, please wait...

ALPN Latest Social Stream


Loading social stream, please wait...

View Full ALPN Social Stream

Latest ALPN News From Around the Web

Below are the latest news stories about ALPINE IMMUNE SCIENCES INC that investors may wish to consider to help them evaluate ALPN as an investment opportunity.

Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie

SEATTLE, December 21, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company has amended the previously announced 2020 option and license agreement with AbbVie for acazicolcept.

Yahoo | December 21, 2023

Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year?

Here is how Alpine Immune Sciences, Inc. (ALPN) and Corbus Pharmaceuticals (CRBP) have performed compared to their sector so far this year.

Yahoo | December 19, 2023

Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SEATTLE, December 18, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that Mitchell Gold, M.D., Executive Chairman and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 7:30 am PT/10:30 am ET, and the Company will participate in one-on-one investor meetings.

Yahoo | December 18, 2023

Optimistic Investors Push Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Up 41% But Growth Is Lacking

Despite an already strong run, Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shares have been powering on, with a gain...

Yahoo | December 18, 2023

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical

Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article.

Yahoo | December 12, 2023

Read More 'ALPN' Stories Here

ALPN Price Returns

1-mo N/A
3-mo 65.15%
6-mo 234.55%
1-year 448.27%
3-year 597.85%
5-year 1,369.91%
YTD 240.87%
2023 159.32%
2022 -46.93%
2021 9.92%
2020 228.13%
2019 4.35%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!